Stevanato Group S.p.A. (STVN) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Stevanato Group S.p.A. (NYSE: STVN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $19.38 (-4.25% 1D, market cap $5.29B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, STVN ranks #215 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), STVN carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MMSI (Merit Medical Systems Inc.) holds a C+ grade (68/100 RQD, P/E 43.4x, ROIC 7.8%, cap $5.17B) and MMED (MiniMed Group Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -3.9%, cap $5.14B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
For Stevanato Group S.p.A. (STVN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #215 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 3.7% FCF Margin ($148.1M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
While STVN currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.46) and Max Pain ($20.35) forces dealer call-delta covering toward $28.35.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Stevanato Group S.p.A. (STVN) dropped -4.25% to $19.38, trading at 46% of its 52-week range ($12.89 – $27). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third qu
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, an
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Read more here.
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on STVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for STVN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Stevanato Group S.p.A. (STVN) ranks #215 by composite RQD confidence (54/100, grade D+) and #156 by equity capitalization ($5.29B). Within this direct 5-issuer industry benchmark cohort, MMSI leads on earnings valuation at 43.4x trailing P/E, while HAE leads on capital efficiency and profitability with 8.4% ROIC and 59.0% gross margin. HAE currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with STVN at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STVN
ACTIVE
Stevanato Group S.p.A. | D+ | 54/100 | — | — | — | -4.25% | $5.29B | Benchmark Subject |
| MMSI Merit Medical Systems Inc. | C+ | 68/100 | 43.4x | 48.7% | 7.8% | -7.66% | $5.17B | /mmsi-vs-stvn → |
| MMED MiniMed Group Inc. | D | 44/100 | — | 54.2% | -3.9% | -5.04% | $5.14B | /mmed-vs-stvn → |
| HAE Haemonetics Corporation | B | 74/100 | — | 59.0% | 8.4% | -0.12% | $5.44B | /hae-vs-stvn → |
| HTFL Heartflow Inc. | D+ | 53/100 | — | 76.8% | -12.0% | -2.44% | $5.13B | /htfl-vs-stvn → |
Stevanato Group S.p.A. (STVN) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $5.29B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Stevanato Group S.p.A. (NYSE: STVN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $19.38 (-4.25% 1D, market cap $5.29B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, STVN ranks #215 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), STVN carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MMSI (Merit Medical Systems Inc.) holds a C+ grade (68/100 RQD, P/E 43.4x, ROIC 7.8%, cap $5.17B) and MMED (MiniMed Group Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -3.9%, cap $5.14B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
For Stevanato Group S.p.A. (STVN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #215 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
STVN last traded at $19.38 (-4.25% on volume of 557,678 shares), positioning the stock -5.28% below its 50-day simple moving average ($20.46) and +7.13% above its 200-day simple moving average ($18.09). Across its 52-week range of $12.89 to $27.00, STVN sits at the 46.0% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($17.89 to $20.87).
Why STVN Stock dropped -4.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, STVN scores 58 out of 100, equating to a D+ grade and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the Cash Engine pillar is weak because the source reports ROIC and FCF yield at 0%. For a prospective investor, the pillar profile suggests that the operating return case is not yet visible in the data, that insider signals do not add support, and that the balance-sheet metrics (Altman Z 2.5, Piotroski F 6/9) are moderate rather than strong. A Beta of 1.0 means the source characterizes the stock as moving in line with the broad market, so the rating does not rest on a volatility argument. The verdict is a quantitative summary of the supplied data, not a recommendation.
Stevanato Group S.p.A. is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry, per the source profile. Not available in source data for products sold, customer base, or revenue model.
Per the Butterfly Supply-Chain Graph, the supply chain is reported as "NONE," with no butterfly links and no proprietary signals. Sector is Health Care and industry is Medical/Dental Instruments. Upstream and downstream dependencies, sector correlations beyond the stated industry, and second-order bottlenecks are not available in source data.
Real-time company headlines, analyst actions, and sector developments for Stevanato Group S.p.A. (STVN) • Click "Debate This Headline" to argue it in the Roar Pit below
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third qu
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, an
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Read more here.
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences
Welcome to the STVN (Stevanato Group S.p.A.) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on STVN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Stevanato Group S.p.A. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on STVN, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $20.24 (52-wk range $17.55 - $22.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).